BioNTech SE (NASDAQ: BNTX) disclosed Monday that it has decided to start a new mRNA manufacturing facility in Singapore. With the foundation of Regional Headquarters for south east Asia in Singapore, the firm is going to grow its worldwide presence in Asia. The new facility decision follows the firm’s decision to choose Singapore as its future regional headquarters.

Furthermore, the firm revealed that the establishment of an mRNA facility is backed by Singapore Economic Development Board. It has been declared that the new facility will offer the regional and global delivery capability of BioNTech’s an ever-increasing pipeline of mRNA-based product candidates, while at the same time a quick response manufacturing capacity for south east Asia to respond to the possible pandemic warnings.

Additionally, the new mRNA facility is consistent with the mission of the firm to develop next-generation immunotherapies to enhance the health of people all around the globe. Moreover, the new mRNA manufacturing facility will utilize the advanced manufacturing and digital infrastructure. It will be furnished to create a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer.

BNTX is also gearing up to start its Singapore office and commence construction of the manufacturing facility in 2021 after getting the required authorization. The firm expects that the site could be effective as early as 2023 and will generate around 80 jobs in Singapore.